Literature DB >> 24798833

Rebuttal from Dr Rho et al.

Jason Rho, Nancy Ho, Vinay Prasad.   

Abstract

Mesh:

Substances:

Year:  2014        PMID: 24798833      PMCID: PMC4011656          DOI: 10.1378/chest.14-0115

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


× No keyword cloud information.
  4 in total

1.  Point: were industry-sponsored roflumilast trials appropriate? Yes.

Authors:  Samy Suissa; Klaus F Rabe
Journal:  Chest       Date:  2014-05       Impact factor: 9.410

Review 2.  Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.

Authors:  Jimmy Chong; Bonnie Leung; Phillippa Poole
Journal:  Cochrane Database Syst Rev       Date:  2013-11-04

Review 3.  Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.

Authors:  Yuji Oba; Nazir A Lone
Journal:  Ther Adv Respir Dis       Date:  2012-11-29       Impact factor: 4.031

4.  Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol.

Authors:  Peter M A Calverley; Fernando J Martinez; Leonardo M Fabbri; Udo-Michael Goehring; Klaus F Rabe
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-06-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.